Literature DB >> 29666183

Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.

Zoltan Ujfalusi1,2, Carlos D Vera3, Srbolujub M Mijailovich4, Marina Svicevic5, Elizabeth Choe Yu6, Masataka Kawana7, Kathleen M Ruppel7, James A Spudich7, Michael A Geeves8, Leslie A Leinwand9.   

Abstract

Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) can cause arrhythmias, heart failure, and cardiac death. Here, we functionally characterized the motor domains of five DCM-causing mutations in human β-cardiac myosin. Kinetic analyses of the individual events in the ATPase cycle revealed that each mutation alters different steps in this cycle. For example, different mutations gave enhanced or reduced rate constants of ATP binding, ATP hydrolysis, or ADP release or exhibited altered ATP, ADP, or actin affinity. Local effects dominated, no common pattern accounted for the similar mutant phenotype, and there was no distinct set of changes that distinguished DCM mutations from previously analyzed HCM myosin mutations. That said, using our data to model the complete ATPase contraction cycle revealed additional critical insights. Four of the DCM mutations lowered the duty ratio (the ATPase cycle portion when myosin strongly binds actin) because of reduced occupancy of the force-holding A·M·D complex in the steady state. Under load, the A·M·D state is predicted to increase owing to a reduced rate constant for ADP release, and this effect was blunted for all five DCM mutations. We observed the opposite effects for two HCM mutations, namely R403Q and R453C. Moreover, the analysis predicted more economical use of ATP by the DCM mutants than by WT and the HCM mutants. Our findings indicate that DCM mutants have a deficit in force generation and force-holding capacity due to the reduced occupancy of the force-holding state.
© 2018 Ujfalusi et al.

Entities:  

Keywords:  actin and myosin ATPase; cardiac muscle; cardiac myosin; cardiomyopathy; computer modeling; dilated cardiomyopathy; duty ratio; heart disease; human cardiomyopathy; hypertrophic cardiomyopathy; kinetic modeling; kinetics; mechanotransduction; molecular motor

Mesh:

Substances:

Year:  2018        PMID: 29666183      PMCID: PMC5995530          DOI: 10.1074/jbc.RA118.001938

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Biochemical studies of myosin.

Authors:  K M Trybus
Journal:  Methods       Date:  2000-12       Impact factor: 3.608

Review 2.  Regulation of contraction in striated muscle.

Authors:  A M Gordon; E Homsher; M Regnier
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

3.  Myo1c mutations associated with hearing loss cause defects in the interaction with nucleotide and actin.

Authors:  Nancy Adamek; Michael A Geeves; Lynne M Coluccio
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

4.  Comparison of two murine models of familial hypertrophic cardiomyopathy.

Authors:  B K McConnell; D Fatkin; C Semsarian; K A Jones; D Georgakopoulos; C T Maguire; M J Healey; J O Mudd; I P Moskowitz; D A Conner; M Giewat; H Wakimoto; C I Berul; F J Schoen; D A Kass; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  2001-03-02       Impact factor: 17.367

5.  A new mechanokinetic model for muscle contraction, where force and movement are triggered by phosphate release.

Authors:  David A Smith
Journal:  J Muscle Res Cell Motil       Date:  2014-10-16       Impact factor: 2.698

6.  Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin.

Authors:  Arjun S Adhikari; Kristina B Kooiker; Saswata S Sarkar; Chao Liu; Daniel Bernstein; James A Spudich; Kathleen M Ruppel
Journal:  Cell Rep       Date:  2016-12-13       Impact factor: 9.423

Review 7.  The genetics of dilated cardiomyopathy.

Authors:  Lisa Dellefave; Elizabeth M McNally
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

8.  Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants.

Authors:  Margaret V Westfall; Andrea R Borton; Faris P Albayya; Joseph M Metzger
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

9.  Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy.

Authors:  Ray E Hershberger; Sharie B Parks; Jessica D Kushner; Duanxiang Li; Susan Ludwigsen; Petra Jakobs; Deirdre Nauman; Donna Burgess; Julie Partain; Michael Litt
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

Review 10.  Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca(2+)-sensitivity in the pathogenesis of cardiomyopathy.

Authors:  Andrew E Messer; Steven B Marston
Journal:  Front Physiol       Date:  2014-08-25       Impact factor: 4.566

View more
  25 in total

Review 1.  Modelling sarcomeric cardiomyopathies with human cardiomyocytes derived from induced pluripotent stem cells.

Authors:  Lorenzo R Sewanan; Stuart G Campbell
Journal:  J Physiol       Date:  2019-02-06       Impact factor: 5.182

Review 2.  Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.

Authors:  Cheavar A Blair; Beth L Pruitt
Journal:  Adv Healthc Mater       Date:  2020-04-09       Impact factor: 9.933

3.  Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.

Authors:  Wanjian Tang; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

4.  Myocardial-specific ablation of Jumonji and AT-rich interaction domain-containing 2 (Jarid2) leads to dilated cardiomyopathy in mice.

Authors:  Eunjin Cho; HyunJun Kang; Dae-Ki Kang; Youngsook Lee
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

5.  Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties.

Authors:  Carlos D Vera; Chloe A Johnson; Jonathan Walklate; Arjun Adhikari; Marina Svicevic; Srboljub M Mijailovich; Ariana C Combs; Stephen J Langer; Kathleen M Ruppel; James A Spudich; Michael A Geeves; Leslie A Leinwand
Journal:  J Biol Chem       Date:  2019-10-03       Impact factor: 5.157

6.  The ATPase cycle of human muscle myosin II isoforms: Adaptation of a single mechanochemical cycle for different physiological roles.

Authors:  Chloe A Johnson; Jonathan Walklate; Marina Svicevic; Srboljub M Mijailovich; Carlos Vera; Anastasia Karabina; Leslie A Leinwand; Michael A Geeves
Journal:  J Biol Chem       Date:  2019-08-06       Impact factor: 5.157

7.  Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Authors:  Wanjian Tang; Jinghua Ge; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  Biophys J       Date:  2021-04-20       Impact factor: 3.699

Review 8.  Beyond genomics-technological advances improving the molecular characterization and precision treatment of heart failure.

Authors:  Kory J Lavine; Michael J Greenberg
Journal:  Heart Fail Rev       Date:  2020-09-03       Impact factor: 4.214

9.  Controlling load-dependent kinetics of β-cardiac myosin at the single-molecule level.

Authors:  Chao Liu; Masataka Kawana; Dan Song; Kathleen M Ruppel; James A Spudich
Journal:  Nat Struct Mol Biol       Date:  2018-06-04       Impact factor: 15.369

10.  Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition.

Authors:  Julien Robert-Paganin; Daniel Auguin; Anne Houdusse
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.